Rebecca A. Shatsky, MD

Dr. Adam Brufsky concludes the discussion by asking the panel to reflect on the most significant unmet needs in the management of HR-positive/HER2-negative metastatic breast cancer and the future direction of the field.

Dr. Adam Brufsky and the panel conclude the program by exploring future treatment considerations in HR-positive/HER2-negative metastatic breast cancer, including the expanding number of available oral SERDs and the factors that may influence treatment selection.

Dr. Adam Brufsky and the panel conclude their discussion by examining the increasingly complex treatment landscape for patients with HR-positive/HER2-negative metastatic breast cancer who experience recurrence after receiving modern adjuvant therapies.

Dr. Adam Brufsky and the panel shift their focus to early-stage HR-positive/HER2-negative breast cancer and discuss emerging endocrine therapy strategies that may influence future treatment paradigms.

Dr. Adam Brufsky and the panel continue their discussion of oral SERDs in HR-positive/HER2-negative metastatic breast cancer, focusing on how emerging clinical data may influence treatment sequencing after progression on CDK4/6 inhibitor-based therapy.

Dr. Adam Brufsky leads a discussion on one of the most debated topics in HR-positive/HER2-negative metastatic breast cancer: the use of oral SERDs and the potential role of molecular monitoring to guide treatment changes before radiographic progression.

Dr. Adam Brufsky and the panel transition to a discussion of oral selective estrogen receptor degraders (SERDs) and their evolving role in the management of HR-positive/HER2-negative metastatic breast cancer.

Dr. Adam Brufsky and the panel continue their discussion of treatment sequencing in HR-positive/HER2-negative metastatic breast cancer, focusing on the role of molecular profiling and biomarker-directed therapy following progression on CDK4/6 inhibitor-based treatment.

Dr. Adam Brufsky and the panel examine treatment decision-making following progression on first-line CDK4/6 inhibitor-based therapy in patients with HR-positive/HER2-negative metastatic breast cancer.

Dr. Adam Brufsky and the panel discuss the practical implementation of PI3K-directed triplet therapy in patients with HR-positive/HER2-negative metastatic breast cancer, focusing on treatment selection, sequencing considerations, and toxicity management.

Dr. Adam Brufsky leads a discussion on the evolving role of triplet therapy in HR-positive/HER2-negative metastatic breast cancer, focusing on the clinical implications of the INAVO-120 study and how its findings may influence treatment selection.

Dr. Adam Brufsky leads a discussion on the evolving role of triplet therapy in HR-positive/HER2-negative metastatic breast cancer, focusing on the clinical implications of the INAVO-120 study and how its findings may influence treatment selection.

Dr. Adam Brufsky opens the discussion by introducing the evolving treatment landscape for patients with HR-positive/HER2-negative metastatic breast cancer.

Experts share vital insights on managing HR-positive breast cancer, emphasizing education, patient quality of life, and the evolving landscape of therapies.

Engaging Long-Term HR Positive Metastatic Patients in Shared Decision Making

Clinicians explore essential pre-treatment assessments and monitoring strategies to manage toxicities from new cancer therapies effectively.

Early intervention in cancer treatment aims to enhance patient quality of life and longevity, balancing therapy effectiveness with individual needs.

Experts discuss the evolving landscape of breast cancer treatment, emphasizing the importance of ctDNA testing for personalized therapy decisions.

Experts discuss balancing efficacy and quality of life in SERD therapies, highlighting unique toxicities and the importance of patient education.

Early detection of ESR1 mutations in breast cancer enhances treatment strategies, potentially improving patient outcomes and quality of life.

Clinicians explore the differences between EMERALD and EMBER3 trials, focusing on patient characteristics, treatment efficacy, and future therapy roles.

Oral SERDs emerge as a standard treatment for HR-positive, HER2-negative metastatic breast cancer, especially for patients with ESR1 mutations.

Oral SERDs emerge as a standard treatment for HR-positive, HER2-negative metastatic breast cancer, especially for patients with ESR1 mutations.

Experts discuss the impact of biomarkers and treatment duration on decision-making for CDK4/6 inhibitors in breast cancer adjuvant therapy.

Discover effective strategies for managing toxicities in patients using CDK4/6 inhibitors, ensuring adherence and optimal treatment outcomes.

Clinicians explore barriers to adjuvant CDK4/6-inhibitor therapy, emphasizing education and streamlined communication to improve patient outcomes.

Experts discuss advancements in HR-positive breast cancer treatment, focusing on CDK4/6 inhibitors, SERDs, and early intervention strategies.

Experts discuss advancements in HR-positive breast cancer treatment, focusing on CDK4/6 inhibitors, SERDs, and early intervention strategies.

CDK4/6 Inhibition in HR-Positive Breast Cancer: Evolving Standards in Early and Metastatic Care

Panelists discuss how the field has made exciting strides, with oral selective estrogen receptor degraders (SERDs) likely moving into early-stage disease and the need for alternative antibody-drug conjugate (ADC) payloads beyond topoisomerase I inhibitors to overcome resistance mechanisms.